Tolbutamide + Midazolam + Pexidartinib
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug Interaction Potential
Conditions
Drug Interaction Potential
Trial Timeline
Feb 26, 2018 โ Apr 16, 2021
NCT ID
NCT03291288About Tolbutamide + Midazolam + Pexidartinib
Tolbutamide + Midazolam + Pexidartinib is a phase 1 stage product being developed by Daiichi Sankyo for Drug Interaction Potential. The current trial status is completed. This product is registered under clinical trial identifier NCT03291288. Target conditions include Drug Interaction Potential.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03291288 | Phase 1 | Completed |
Competing Products
20 competing products in Drug Interaction Potential